# Assignment 5 diffusion test and evidence record

Date: 2026-10-24 (America/New_York). Case organizations are hypothetical. The technology and application are held constant across all three cases.

## Original evidence checked

1. [AMA 2026 Physician Survey on Augmented Intelligence](https://www.ama-assn.org/sites/ama-assn.org/files/2026-03/physician-ai-sentiment-report_0.pdf), pp. 4–6, 10 and 14–15. Fielded January 15–February 2, 2026; 1,692 participating physicians. It reports broad AI use/awareness, named use cases and adoption prerequisites. Its 81% is **not** ambient-scribe adoption. Results are self-reported and question-level denominators vary. Checked against the original AMA report on October 24, 2026.
2. [Wright et al., JAMIA 2026, 33(2):457–461](https://academic.oup.com/jamia/article/33/2/457/8307782). At Vanderbilt, an ambient scribe was offered to more than 2,400 ambulatory/ED clinicians in January 2025; by March 31, 1,223 had ever used it, and 20.1% of all visit notes included it. This is an original single-system operational report. It describes clinician champions, training, EHR integration and device/consent barriers; those are case mechanisms, not causal estimates of national uptake. Checked October 24, 2026.
3. [Afshar et al., NEJM AI, November 26, 2025](https://pmc.ncbi.nlm.nih.gov/articles/PMC12858090/). Pragmatic randomized implementation with 66 eligible volunteers across eight ambulatory specialties and one health system: 27,092 of 71,487 notes used ambient AI; note-writing time fell by 0.36 hours/day. This supports a possible relative advantage and trial feasibility, not a market penetration rate or a guaranteed local result. Checked October 24, 2026.

**Weak claim:** “Ambient scribing has crossed into the U.S. early majority.” The evidence above does not supply a representative U.S. ambient-scribe denominator, comparable peer series, or a consistent measure of availability, ever-use, active use and work share. The revised agent abstains from this stage label.

## Actual run sequence

1. Ran `python3 tools/check_frozen_core.py`: **FROZEN CORE INTACT**.
2. Ran `python3 tools/new_agent.py diffusion_agent ...` and `python3 tools/build_prompt.py` for the primary case with v0.1. Generated `work/diffusion_agent_primary_prompt.txt`. In this Codex/ChatGPT session, produced and saved the v0.1 diagnostic JSON at `responses/diagnostic_primary_response.json`. Ran the supplied validator: **VALIDATION PASSED**. The content was still wrong: it inferred “early majority” from broad AI survey use and a single academic deployment. The validator checks structure, not evidentiary reasoning.
3. Revised only the student-editable specialist instructions and metadata to v0.2. The new instructions require population, geography, time window and use measure for each diffusion statistic; they also separate market stage from organizational posture.
4. Ran the supplied prompt builder separately for `primary.json`, `contrast_1.json`, and `contrast_2.json`; all three packet files were generated in ignored `work/`. Analyzed each packet in this Codex/ChatGPT session and saved structured responses under `responses/`.
5. Ran `python3 tools/validate_response.py` separately on all three revised responses: **VALIDATION PASSED** for each. Ran `python3 agents/diffusion_agent/tests/check_diffusion_contrast.py`: **CONTEXT CONTRAST PASSED: 3 cases; general/application/evidence stable; timing differs**. Ran `python3 tools/check_frozen_core.py`: **FROZEN CORE INTACT**. Ran `git diff --check`: no whitespace errors.

## Inspect the contrast

| Context | Stable evidence and finding | Bounded timing implication |
| --- | --- | --- |
| Conservative safety-net primary-care network | National ambient-scribe stage indeterminate; same AMA, Vanderbilt and randomized-trial facts | Readiness work now; consider a small pilot in roughly 6–12 months only after privacy, integration, consent and multilingual quality gates |
| Innovator/early-adopter academic network | Same general and application findings | Small monitored opt-in pilot in roughly 0–3 months after controls |
| Moderate fast-follower network | Same general and application findings | Prepare now; consider pilot in roughly 3–6 months after a comparable peer signal and local checks |

The timing windows are **case-specific professional inferences**, not published forecasts or actual institutional commitments. The contrast script checks saved fields and stated timing; human review checked that the cited sources support the limited claims. It cannot prove the agent will behave correctly for every future case.

## Independent judgment and handoff

The specialist is credible enough for team discussion as a bounded timing aid. The strongest diffusion signal is successful broad availability and measurable note use in a large academic system, not national penetration. The most important inhibitor for the primary scenario is local compatibility and validation capacity. The Adoption Agent should inherit the missing peer denominator and should demand local quality, privacy, cost and workflow evidence before any full adoption decision.

## AI use and verification

ChatGPT/Codex helped draft the factor mapping, case contrast, responses and revised instructions. The published numbers and study scope were checked against the original AMA report and original research articles. The three JSON responses are representative model-assisted analyses in this session; no external model API, live clinical data, or deployed scribe was used.
